Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 323.33 Billion KRW | 26.29% |
| 2022 | 249.03 Billion KRW | 20.5% |
| 2021 | 209.36 Billion KRW | 78.08% |
| 2020 | 108.33 Billion KRW | -28.84% |
| 2019 | 163.67 Billion KRW | 41.17% |
| 2018 | 116.88 Billion KRW | 10.58% |
| 2017 | 106.51 Billion KRW | 10.22% |
| 2016 | 56.84 Billion KRW | -65.85% |
| 2015 | 271.98 Billion KRW | 271.57% |
| 2014 | 59.84 Billion KRW | -22.69% |
| 2013 | 88.98 Billion KRW | 15.37% |
| 2012 | 83.35 Billion KRW | 37.96% |
| 2011 | 59.06 Billion KRW | 210.92% |
| 2010 | 20.07 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 82.45 Billion KRW | -19.86% |
| 2024 Q3 | 50.97 Billion KRW | -39.84% |
| 2024 Q1 | 100.85 Billion KRW | 6.09% |
| 2023 Q2 | 180.18 Billion KRW | 102.51% |
| 2023 Q3 | 198.84 Billion KRW | 10.36% |
| 2023 Q4 | 99.66 Billion KRW | -49.88% |
| 2023 FY | - KRW | 26.29% |
| 2023 Q1 | 88.97 Billion KRW | 43.88% |
| 2022 FY | - KRW | 20.5% |
| 2022 Q4 | 61.84 Billion KRW | -15.97% |
| 2022 Q3 | 73.59 Billion KRW | 31.86% |
| 2022 Q1 | 64.78 Billion KRW | 7.22% |
| 2022 Q2 | 55.81 Billion KRW | -13.86% |
| 2021 Q2 | 39.93 Billion KRW | -25.35% |
| 2021 Q1 | 53.5 Billion KRW | -16.46% |
| 2021 Q4 | 60.42 Billion KRW | 3.11% |
| 2021 Q3 | 58.6 Billion KRW | 46.72% |
| 2021 FY | - KRW | 78.08% |
| 2020 Q2 | 26.04 Billion KRW | -42.51% |
| 2020 Q3 | -16.06 Billion KRW | -161.71% |
| 2020 Q4 | 64.05 Billion KRW | 498.61% |
| 2020 FY | - KRW | -28.84% |
| 2020 Q1 | 45.29 Billion KRW | -3.09% |
| 2019 Q2 | 39.44 Billion KRW | -6.15% |
| 2019 Q4 | 46.73 Billion KRW | 18.43% |
| 2019 FY | - KRW | 41.17% |
| 2019 Q1 | 42.03 Billion KRW | 174.22% |
| 2019 Q3 | 39.46 Billion KRW | 0.04% |
| 2018 Q2 | 38.78 Billion KRW | 6.95% |
| 2018 FY | - KRW | 10.58% |
| 2018 Q4 | 15.32 Billion KRW | -46.0% |
| 2018 Q3 | 28.38 Billion KRW | -26.82% |
| 2018 Q1 | 36.26 Billion KRW | 134.04% |
| 2017 Q4 | 15.49 Billion KRW | -53.04% |
| 2017 FY | - KRW | 10.22% |
| 2017 Q2 | 20.12 Billion KRW | -48.09% |
| 2017 Q1 | 38.77 Billion KRW | 218.4% |
| 2017 Q3 | 33 Billion KRW | 63.94% |
| 2016 FY | - KRW | -65.85% |
| 2016 Q1 | 46.43 Billion KRW | -77.23% |
| 2016 Q2 | 30.95 Billion KRW | -33.33% |
| 2016 Q4 | 12.17 Billion KRW | 54.75% |
| 2016 Q3 | 7.86 Billion KRW | -74.58% |
| 2015 Q2 | 9.36 Billion KRW | -60.3% |
| 2015 FY | - KRW | 271.57% |
| 2015 Q1 | 23.59 Billion KRW | -0.64% |
| 2015 Q4 | 203.97 Billion KRW | 346.82% |
| 2015 Q3 | 45.64 Billion KRW | 387.47% |
| 2014 Q1 | 26.13 Billion KRW | 7.05% |
| 2014 Q4 | 23.74 Billion KRW | 106.94% |
| 2014 Q3 | 11.47 Billion KRW | -25.72% |
| 2014 FY | - KRW | -22.69% |
| 2014 Q2 | 15.44 Billion KRW | -40.91% |
| 2013 Q4 | 24.41 Billion KRW | -12.02% |
| 2013 Q1 | 26.95 Billion KRW | 2.15% |
| 2013 Q3 | 27.75 Billion KRW | 37.28% |
| 2013 Q2 | 20.21 Billion KRW | -25.0% |
| 2013 FY | - KRW | 15.37% |
| 2012 Q4 | 26.38 Billion KRW | -7.74% |
| 2012 FY | - KRW | 37.96% |
| 2012 Q2 | 36.45 Billion KRW | 238.45% |
| 2012 Q1 | 10.77 Billion KRW | 0.0% |
| 2012 Q3 | 28.6 Billion KRW | -21.54% |
| 2011 Q3 | 10.12 Billion KRW | -6.52% |
| 2011 Q1 | 12.25 Billion KRW | 0.0% |
| 2011 FY | - KRW | 210.92% |
| 2011 Q2 | 10.82 Billion KRW | -11.65% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | - KRW | 0.0% |
| 2010 Q3 | 2.24 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -6555.266% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | -128.725% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 604.927% |
| HANDOK Inc. | 35.06 Billion KRW | -822.058% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 31292.648% |
| Yuhan Corporation | 127.43 Billion KRW | -153.73% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -761.743% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 1590.879% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -6379.244% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -2038.709% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -9351.552% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -7043.318% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -811.152% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -6555.266% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 1850.424% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -4832.678% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 755.96% |
| JW Holdings Corporation | 187.88 Billion KRW | -72.092% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 731.163% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | -14.001% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -262.399% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 972.303% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -2347.73% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -2633.674% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -1633.251% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -6555.266% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -488.17% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | -96.064% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -262.399% |
| Yuhan Corporation | 127.43 Billion KRW | -153.73% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -865.874% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -4126.697% |
| Suheung Co., Ltd. | 77.02 Billion KRW | -319.761% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | -262.399% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -782.599% |
| Korea United Pharm Inc. | 70.78 Billion KRW | -356.815% |
| CKD Bio Corp. | -1.63 Billion KRW | 19931.121% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -549.359% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -892.999% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -778.381% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 972.303% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | -419.128% |
| Boryung Corporation | 114.28 Billion KRW | -182.912% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 1157.747% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -2038.709% |
| JW Lifescience Corporation | 50.82 Billion KRW | -536.121% |